A Phase 3 interventional study of Nivolumab and Cisplatin in Non Small Cell Lung Cancer, sponsored by Bristol-Myers Squibb. Completed at 138 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-06.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung — 22 open to participants now, 44 under way, 6 of them phase 3. Nivolumab · Carcinoma, Non-Small-Cell Lung.
Among the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung, this one is the 13th largest by enrollment, is one of 24 that started in 2017, is one of 24 in phase 3, and was the 32nd registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →22 of the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
University of Chicago · Sites in United States
Ages 18+
Washington University School of Medicine · Sites in United States
Ages 18+
Liza Villaruz, MD · Sites in United States
Ages 18+
Diwakar Davar · Sites in United States
Ages 18+
EuroCityClinic LLC · Sites in Russia
Ages 18+
By country, each count listing its studies:
Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, nivolumab is the treatment under test here. Read study by study →
120 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 78 · Phase 3 24 · Phase 4 2
First in 2006; this study’s year is marked. 24 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 505 is above the median of 62 across 6,023 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 66 across the 120 interventional studies. Of the 62 that completed or were terminated, 44 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 120 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
131 studies in Carcinoma, Non-Small-Cell Lung by Bristol-Myers Squibb: 21 open now, 35 under way, 10 of them phase 3. Of 91 finished, 47 (52%) have results posted.
Among the 131 studies in Carcinoma, Non-Small-Cell Lung by Bristol-Myers Squibb, this one is the 19th largest by enrollment of the 107 interventional ones that give a count, is one of 9 that started in 2017, is one of 27 in phase 3, and was the 57th registered.
Bristol-Myers Squibb’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
13 of the studies testing nivolumab in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02595944Phase 3National Cancer Institute (NCI)Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial) | 2027-05-31 |
| NCT03527108Fox Chase Cancer CenterNivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC | 2026-12 |
| NCT05597800Universita di VeronaNivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome | 2026-12-31 |
| NCT06946797Bristol-Myers SquibbA Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC) | 2027-02-05 |
| NCT06275360VA Office of Research and DevelopmentRepositioning Immunotherapy in VetArans With Lung Cancer | 2027-02-28 |
Add all 13 to your calendar (.ics) → With an account.
Among the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Bristol-Myers Squibb’s 131 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
The purpose of this neoadjuvant study is to compare nivolumab plus chemotherapy and chemotherapy alone in terms of safety and effectiveness, and to describe nivolumab plus ipilimumab's safety and effectiveness in treating resectable NSCLC.
This study has multiple primary endpoints.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Specified dose on specified days
Drug: Cisplatin · Drug: Vinorelbine · Drug: Gemcitabine · Drug: Docetaxel · Drug: Pemetrexed · Drug: Carboplatin · Drug: Paclitaxel
Specified dose on specified days
Biological: Nivolumab · Drug: Cisplatin · Drug: Gemcitabine · Drug: Pemetrexed · Drug: Carboplatin · Drug: Paclitaxel
Specified dose on specified days
Biological: Nivolumab · Biological: Ipilimumab
Specified dose on specified days
Also known as: BMS-936558, Opdivo
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
This arm is closed and no longer enrolling patients.
Also known as: BMS-734016, Yervoy
Event-Free Survival (EFS)
Event-free survival (EFS) is defined as the length of time from randomization to any of the following events: any progression of disease precluding surgery, progression or recurrence disease based on blinded independent central review (BICR) assessment per response evaluation criteria in solid tumors (RECIST) 1.1 after surgery, or death due to any cause. Participants who don't undergo surgery for reason other than progression will be considered to have an event at progression or death. Progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).
Time frame: From randomization to disease progression, reoccurrence, or death due to any cause. (Up to a median of 30 months)
Pathologic Complete Response (pCR) Rate
Pathologic complete response (pCR) rate is defined as the number of randomized participants with absence of residual tumor in lung and lymph nodes as evaluated by blinded independent pathological review (BIPR).
Time frame: From randomization up to a median of 30 months after randomization.
Major Pathologic Response (MPR) Rate
Major pathologic response (MPR) rate is defined as number of randomized participants with \</= 10% residual tumor in lung and lymph nodes as evaluated by blinded independent pathological review (BIPR). Viable tumors in situ carcinoma should not be included in MPR calculation.
Time frame: From randomization up to a median of 30 months after randomization.
Overall Survival (OS)
Overall survival (OS) is defined as the time between the date of randomization and the date of death. OS will be censored on the last date a participant was known to be alive.
Time frame: From randomization to the date of death (Up to approximately 93 months)
Time to Death or Distant Metastases (TTDM)
TTDM is defined as the time between the date of randomization and the first date of distant metastasis or the date of death in the absence of distant metastasis. Distant metastasis is defined as any new lesion that is outside of the thorax using blinded independent central review (BICR) according to response evaluation criteria in solid tumors (RECIST) 1.1. Patients who have not developed distant metastasis or died at the time of analysis will be censored on the date of their last evaluable tumor assessment.
Time frame: From randomization to the first date of distant metastasis or the date of death in the absence of distant metastasis (Up to approximately 84 months)
| Milestone | Arm A: Nivo 3 mg/kg + Ipi 1 mg/kg | Arm B: Platinum Doublet Chemo | Arm C: Nivo 360 mg + Platinum Doublet Chemo |
|---|---|---|---|
| Started | 113 | 213 | 179 |
| All concurrently randomized participants in arms b and c | 0 | 179 | 179 |
| Completed | 112 | 207 | 176 |
| Not completed | 1 | 6 | 3 |
| Withdrew: Adverse event unrelated to study drug | 0 | 0 | 1 |
| Withdrew: Participant withdrew consent | 0 | 3 | 0 |
| Withdrew: Participant no longer meets study criteria | 1 | 3 | 2 |
| Milestone | Arm A: Nivo 3 mg/kg + Ipi 1 mg/kg | Arm B: Platinum Doublet Chemo | Arm C: Nivo 360 mg + Platinum Doublet Chemo |
|---|---|---|---|
| Started | 111 | 208 | 176 |
| All treated participants from concurrently randomized arms b and c | 0 | 176 | 176 |
| Completed | 101 | 177 | 165 |
| Not completed | 10 | 31 | 11 |
| Withdrew: Participant request to discontinue study treatment | 0 | 7 | 0 |
| Withdrew: Participant withdrew consent | 0 | 4 | 0 |
| Withdrew: Participant no longer meets study criteria | 0 | 1 | 0 |
| Withdrew: Disease progression | 3 | 2 | 1 |
| Withdrew: Study drug toxicity | 6 | 14 | 10 |
| Withdrew: Death | 1 | 0 | 0 |
| Withdrew: Adverse event unrelated to study treatment | 0 | 3 | 0 |
| Milestone | Arm A: Nivo 3 mg/kg + Ipi 1 mg/kg | Arm B: Platinum Doublet Chemo | Arm C: Nivo 360 mg + Platinum Doublet Chemo |
|---|---|---|---|
| Started | 37 | 47 | 26 |
| Completed | 28 | 41 | 22 |
| Not completed | 9 | 6 | 4 |
| Withdrew: Disease progression | 1 | 0 | 0 |
| Withdrew: Study drug toxicity | 4 | 5 | 1 |
| Withdrew: Adverse event unrelated to study drug | 1 | 0 | 1 |
| Withdrew: Participant request to discontinue treatment | 3 | 1 | 1 |
| Withdrew: Other reasons | 0 | 0 | 1 |
Event-free survival (EFS) is defined as the length of time from randomization to any of the following events: any progression of disease precluding surgery, progression or recurrence disease based on blinded independent central review (BICR) assessment per response evaluation criteria in solid tumors (RECIST) 1.1 after surgery, or death due to any cause. Participants who don't undergo surgery for reason other than progression will be considered to have an event at progression or death. Progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).
| Months | Arm B: Platinum Doublet Chemo | Arm C: Nivo 360 mg + Platinum Doublet Chemo |
|---|---|---|
| Event-Free Survival (EFS) | 20.80 (14.03 to 26.71) | 31.57 (30.16 to NA) |
Pathologic complete response (pCR) rate is defined as the number of randomized participants with absence of residual tumor in lung and lymph nodes as evaluated by blinded independent pathological review (BIPR).
| Participants | Arm B: Platinum Doublet Chemo | Arm C: Nivo 360 mg + Platinum Doublet Chemo |
|---|---|---|
| Pathologic Complete Response (pCR) Rate | 4 | 43 |
Event-free survival (EFS) is defined as the length of time from randomization to any of the following events: any progression of disease precluding surgery, progression or recurrence disease based on blinded independent central review (BICR) assessment per response evaluation criteria in solid tumors (RECIST) 1.1 after surgery, or death due to any cause. Participants who don't undergo surgery for reason other than progression will be considered to have an event at progression or death. Progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).
| Months | Arm B: Platinum Doublet Chemo | Arm C: Nivo 360 mg + Platinum Doublet Chemo |
|---|---|---|
| Event-Free Survival (EFS) | 21.06 (16.53 to 36.76) | 59.60 (31.57 to NA) |
Major pathologic response (MPR) rate is defined as number of randomized participants with \</= 10% residual tumor in lung and lymph nodes as evaluated by blinded independent pathological review (BIPR). Viable tumors in situ carcinoma should not be included in MPR calculation.
| Participants | Arm B: Platinum Doublet Chemo | Arm C: Nivo 360 mg + Platinum Doublet Chemo |
|---|---|---|
| Major Pathologic Response (MPR) Rate | 16 | 66 |
Overall survival (OS) is defined as the time between the date of randomization and the date of death. OS will be censored on the last date a participant was known to be alive.
| Months | Arm B: Platinum Doublet Chemo | Arm C: Nivo 360 mg + Platinum Doublet Chemo |
|---|---|---|
| Overall Survival (OS) | 73.72 (47.34 to NA) | NA (NA to NA) |
TTDM is defined as the time between the date of randomization and the first date of distant metastasis or the date of death in the absence of distant metastasis. Distant metastasis is defined as any new lesion that is outside of the thorax using blinded independent central review (BICR) according to response evaluation criteria in solid tumors (RECIST) 1.1. Patients who have not developed distant metastasis or died at the time of analysis will be censored on the date of their last evaluable tumor assessment.
| Months | Arm B: Platinum Doublet Chemo | Arm C: Nivo 360 mg + Platinum Doublet Chemo |
|---|---|---|
| Time to Death or Distant Metastases (TTDM) | 36.76 (24.74 to 56.80) | 64.66 (49.02 to NA) |
Collected over All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A: Nivo 3 mg/kg + Ipi 1 mg/kg | 46/112 (41.1%) | 30/111 (27%) | 102/111 (91.9%) |
| Arm B: Platinum Doublet Chemo | 105/214 (49.1%) | 58/208 (27.9%) | 202/208 (97.1%) |
| Arm C: Nivo 360 mg + Platinum Doublet Chemo | 66/179 (36.9%) | 53/176 (30.1%) | 160/176 (90.9%) |
| Event | Arm A: Nivo 3 mg/kg + Ipi 1 mg/kg | Arm B: Platinum Doublet Chemo | Arm C: Nivo 360 mg + Platinum Doublet Chemo |
|---|---|---|---|
| PneumoniaInfections and infestations | 5/111 | 8/208 | 6/176 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 4/111 | 1/208 | 1/176 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/111 | 6/208 | 3/176 |
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/111 | 5/208 | 2/176 |
| VomitingGastrointestinal disorders | 0/111 | 1/208 | 4/176 |
| DiarrhoeaGastrointestinal disorders | 2/111 | 2/208 | 0/176 |
| Postoperative respiratory failureInjury, poisoning and procedural complications | 2/111 | 0/208 | 0/176 |
| Acute kidney injuryRenal and urinary disorders | 0/111 | 2/208 | 3/176 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/111 | 1/208 | 3/176 |
| Post procedural complicationInjury, poisoning and procedural complications | 1/111 | 1/208 | 2/176 |
| Event | Arm A: Nivo 3 mg/kg + Ipi 1 mg/kg | Arm B: Platinum Doublet Chemo | Arm C: Nivo 360 mg + Platinum Doublet Chemo |
|---|---|---|---|
| NauseaGastrointestinal disorders | 24/111 | 105/208 | 73/176 |
| AnaemiaBlood and lymphatic system disorders | 9/111 | 78/208 | 62/176 |
| ConstipationGastrointestinal disorders | 24/111 | 73/208 | 63/176 |
| Decreased appetiteMetabolism and nutrition disorders | 18/111 | 53/208 | 47/176 |
| Neutrophil count decreasedInvestigations | 7/111 | 46/208 | 28/176 |
| FatigueGeneral disorders | 24/111 | 39/208 | 30/176 |
| NeutropeniaBlood and lymphatic system disorders | 1/111 | 39/208 | 32/176 |
| DiarrhoeaGastrointestinal disorders | 18/111 | 34/208 | 21/176 |
| PyrexiaGeneral disorders | 18/111 | 23/208 | 20/176 |
| MalaiseGeneral disorders | 3/111 | 26/208 | 27/176 |
All randomized participants
| Age, Customized(Participants) | Arm A: Nivo 3 mg/kg + Ipi 1 mg/kg | Arm B: Platinum Doublet Chemo | Arm C: Nivo 360 mg + Platinum Doublet Chemo | Total |
|---|---|---|---|---|
| < 65 | 62 | 99 | 93 | 254 |
| >= 65 AND < 75 | 40 | 96 | 75 | 211 |
| >= 75 AND < 85 | 11 | 17 | 11 | 39 |
| >= 85 | 0 | 1 | 0 | 1 |
| Sex: Female, Male(Participants) | Arm A: Nivo 3 mg/kg + Ipi 1 mg/kg | Arm B: Platinum Doublet Chemo | Arm C: Nivo 360 mg + Platinum Doublet Chemo | Total |
|---|---|---|---|---|
| Female | 40 | 65 | 51 | 156 |
| Male | 73 | 148 | 128 | 349 |
| Ethnicity (NIH/OMB)(Participants) | Arm A: Nivo 3 mg/kg + Ipi 1 mg/kg | Arm B: Platinum Doublet Chemo | Arm C: Nivo 360 mg + Platinum Doublet Chemo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 2 | 5 | 0 | 7 |
| Not Hispanic or Latino | 53 | 105 | 100 | 258 |
| Unknown or Not Reported | 58 | 103 | 79 | 240 |
| Race (NIH/OMB)(Participants) | Arm A: Nivo 3 mg/kg + Ipi 1 mg/kg | Arm B: Platinum Doublet Chemo | Arm C: Nivo 360 mg + Platinum Doublet Chemo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 41 | 96 | 86 | 223 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 4 | 5 | 4 | 13 |
| White | 64 | 108 | 89 | 261 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 4 | 4 | 0 | 8 |
Showing the first 100 of 138 sites across 15 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2017 to primary completion in Sep 2021, 54 months.
Results were first posted in Sep 2022, 1 year after primary completion.
Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 54 months is above that.
Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Nivolumab · Cisplatin · Gemcitabine · Pemetrexed · Carboplatin · Paclitaxel · Ipilimumab
Carcinoma, Non-Small-Cell Lung →